Skip to main content

Clinical Trials Using Carfilzomib

Review the clinical trials studying carfilzomib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 25

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Status: Active
Location: 12 locations
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Status: Active
Location: 13 locations
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Status: Active
Location: 10 locations
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Active
Location: 11 locations
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Status: Active
Location: 11 locations
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Status: Active
Location: 10 locations
Horizon Two: HR NDMM (MMRC-100)
Status: Active
Location: 10 locations
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Status: Active
Location: 11 locations
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Status: Active
Location: 6 locations
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Status: Active
Location: 5 locations
Testing an Experimental Approach to Treat Patients with Plasma Cell Leukemia, The QUANTUM Trial
Status: Active
Location: 2 locations
Selinexor in Combination with Carfilzomib, Daratumumab or Pomalidomide, and Dexamethasone for the Treatment of Patients with Multiple Myeloma Relapsing on Current Therapy
Status: Active
Location: 2 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Location: 7 locations
Selinexor in Combination with Carfilzomib, Subcutaneous Isatuximab Administered via an On Body Delivery System, and Dexamethasone for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Status: Active
Location: 2 locations
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Status: Active
Location: 3 locations
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients with Extramedullary Disease
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Belantamab Mafodotin in Combination with Carfilzomib, Pomalidomide, and Dexamethasone for Treatment of Relapsed or Recurrent Multiple Myeloma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients with Multiple Myeloma Who Have Relapsed Shortly after Treatment
Status: Active
Location: ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania
Carfilzomib-Based Chemotherapy before Autologous Stem Cell Transplant for the Treatment of Multiple Myeloma
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
SX-682 in Combination with Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients with High-risk Multiple Myeloma Refractory or in First Relapse
Status: Active
Location: See ClinicalTrials.gov
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin With or Without Autologous Stem Cell Transplantation for the Treatment Relapsed or Refractory Multiple Myeloma or Newly Diagnosed, High Risk Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: 2 locations